⟵ Back to Search Results
BGB-3111-213

Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Beigene Study ID info

BGB-3111-213

ClinicalTrials.gov ID info

NCT03520920

China Drug Trials ID info

CTR20170965

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Study Documents

Study Protocol Statistical Analysis Plan